Andy Chen
Stock Analyst at Wolfe Research
(3.35)
# 970
Out of 4,944 analysts
40
Total ratings
51.85%
Success rate
4.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $427.92 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $22.10 | - | 2 | Aug 4, 2025 | |
| VRNA Verona Pharma | Initiates: Outperform | $170 | $105.24 | +61.54% | 1 | Jul 1, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $49.69 | -1.39% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $19.15 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $46.16 | +19.15% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $55.11 | +10.69% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $11.27 | +86.34% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $20.16 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $29.12 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.41 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $14.47 | +38.26% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $16.50 | +15.15% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $15.51 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $637.48 | +9.34% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $83.46 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $24.64 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $40.46 | +60.65% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $48.73 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $364.00 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.73 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $10.99 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $42.22 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $58.12 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.80 | +44.07% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $390.78 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $121.75 | -65.50% | 1 | Feb 15, 2024 |
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $427.92
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $22.10
Upside: -
Verona Pharma
Jul 1, 2025
Initiates: Outperform
Price Target: $170
Current: $105.24
Upside: +61.54%
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $49.69
Upside: -1.39%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.15
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $46.16
Upside: +19.15%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $55.11
Upside: +10.69%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $11.27
Upside: +86.34%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $20.16
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $29.12
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.41
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $14.47
Upside: +38.26%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $16.50
Upside: +15.15%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $15.51
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $637.48
Upside: +9.34%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $83.46
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $24.64
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $40.46
Upside: +60.65%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $48.73
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $364.00
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $18.73
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $10.99
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $42.22
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $58.12
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.80
Upside: +44.07%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $390.78
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $121.75
Upside: -65.50%